11:25 AM
 | 
Jan 12, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Axovant reports Phase II data for dementia candidate nelotanserin

Axovant Sciences Ltd. (NASDAQ:AXON) reported data from 27 evaluable patients with dementia with Lewy bodies (DLB) and Parkinson's disease dementia who were experiencing frequent and recurrent visual hallucinations in a Phase II trial evaluating nelotanserin. Compared to placebo, nelotanserin non-significantly improved Unified Parkinson's Disease Rating Scale (UPDRS) Part III motor scores by 3.12 points (unadjusted p=0.075) and Scale for the Assessment of Positive Symptoms-PD (SAPS-PD) score...

Read the full 306 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >